Table 2.
Hazard ratio and 95% confidence interval of all-cause, CVD and CHD mortality, and combined endpoint including fatal and nonfatal CHD in the ERICO study participants at low and high risk for obstructive sleep apnea
| Crude | Age- and sex- adjusted | Multivariate adjusted | |
|---|---|---|---|
| All-cause mortality | |||
| Low risk for obstructive sleep apnea | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| High risk for obstructive sleep apnea | 1.17 (0.632.17) | 1.31 (0.83-2.07) | 1.29 (0.64-2.61) |
| CVD* mortality | |||
| Low risk for obstructive sleep apnea | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| High risk for obstructive sleep apnea | 1.21 (0.453.24) | 1.23 (0.66-2.29) | 1.65 (0.63-4.38) |
| CHD† mortality | |||
| Low risk for obstructive sleep apnea | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| High risk for obstructive sleep apnea | 1.21 (0.453.24) | 1.24 (0.46-3.34) | 2.85 (0.54-15.12) |
| Combined endpoint (fatal and recurrent nonfatal CHD) | |||
| Low risk for obstructive sleep apnea | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| High risk for obstructive sleep apnea | 2.31 (1.06-5.02) | 2.34 (1.07-5.08) | 4.26 (1.18-15.36) |
*
CVD: cardiovascular disease;
†
CHD: coronary heart disease. Multivariate analysis adjusted for age, sex, diabetes, dyslipidemia, smoking, sedentary lifestyle, previous CHD, family history of CHD, acute coronary syndrome subtype and ejection fraction.